Document:

Exhibit 10.3

 

AMENDMENT NO. 3 TO LOAN AND SECURITY
AGREEMENT

 

This AMENDMENT NO.
3 TO LOAN AND SECURITY AGREEMENT (this “Amendment”), is entered into this 13th day of June, 2016, by and
among (a) INSPIREMD, INC., a Delaware corporation (“US Borrower”), and INSPIRE M.D LTD, a company
organized under the laws of the State of Israel (“ISR Borrower”) (US Borrower and ISR Borrower are hereinafter
jointly and severally, individually and collectively, referred to as “Borrower”), (b) the several banks and
other financial institutions or entities from time to time parties to the Loan Agreement (defined below; collectively, the “Lender”),
and (c) HERCULES CAPITAL, INC., f/k/a Hercules Technology Growth Capital, Inc., a Maryland corporation in its capacity as
administrative agent for itself and the Lender (in such capacity, the “Agent”).

 

WHEREAS, Borrower
and Lender are parties to a certain Loan and Security Agreement, dated as of October 23, 2013, as amended by a certain Amendment
No. 1 dated as of November 19, 2013, and as further amended by a certain Amendment No. 2 dated as of July 23, 2014 (as the same
may from time to time be further amended, modified or supplemented in accordance with its terms, the “Loan Agreement”);
and

 

WHEREAS, in
accordance with Section 11.3 of the Loan Agreement, Borrower and Lender desire to amend the Loan Agreement as provided herein.

 

NOW THEREFORE,
in consideration of the mutual agreements contained in the Loan Agreement and herein and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.                  Defined
Terms. Terms not otherwise defined herein which are defined in the Loan Agreement shall have the same respective
meanings herein as therein.

 

2.                  Amendments
to Loan Agreement. Subject to the satisfaction of the conditions set forth in Section 3 of this Amendment, the Loan Agreement
is hereby amended as follows:

 

		A.	Section 1.1 (Definitions and Rules of Construction). The following definitions set
forth in Section 1.1 of the Loan Agreement shall be amended in their entirety and replaced with the following:

 

“Term
Loan Maturity Date” means (a) if the Interest Only Period Extension Event does not occur on or prior to June 30, 2016,
April 1, 2017, and (b) if the Interest Only Period Extension Event occurs on or prior to June 30, 2016, June 1, 2017

 

“Warrant”
means the warrant entered into in connection with the Term Loan Advance and any subsequent warrant entered into by US Borrower
in favor of Lender.

 

		B.	Section 1.1 (Definitions and Rules of Construction). The Loan Agreement is amended
by inserting the following new definitions to appear alphabetically in Section 1.1 thereof:

 

“2016
Amendment Date” is June 13, 2016.

 

“Equity
Event” means confirmation by Agent and Lender that Borrower has received, after the 2016 Amendment Date, but on or before
June 30, 2016, unrestricted and unencumbered net cash proceeds in an amount of at least Ten Million Dollars ($10,000,000.00) from
the issuance and sale by US Borrower of its equity securities with investors acceptable to Lender.

 

    	1

     

    

 

“Interest
Only Period Extension Event” means that (a) the Equity Event has occurred on or prior to June 30, 2016, or (b)
Agent and Lender have each elected in writing in their sole discretion to suspend the principal payments otherwise due and
payable on July 1, 2016 and August 1, 2016 as set forth in Section 2.1(d).

 

		C.	Section 2.1(d) (Payment of Interest and Principal). The Loan Agreement is amended
by deleting Section 2.1(d) thereof in its entirety and inserting in lieu thereof the following:

 

“(d)          Payment
of Interest and Principal. Borrower will pay interest on the Term Loan Advance on the first (1st) Business Day of each month,
beginning on December 2, 2013. Borrower shall repay the aggregate principal balance of the Term Loan Advance that is outstanding
on the day immediately preceding the Amortization Date, in equal monthly installments of principal and interest (mortgage style)
beginning on the Amortization Date and continuing on the first (1st) Business Day of each month thereafter until the Secured Obligations
(other than inchoate indemnity obligations) are repaid. Notwithstanding the foregoing, so long as no Event of Default has occurred
and is continuing: (a) the principal payment otherwise due and payable on May 1, 2016 shall be suspended but due and payable in
full no later than March 1, 2017, (b) the principal payment otherwise due and payable on June 1, 2016 shall be suspended but due
and payable in full no later than April 1, 2017, (c) only if the Interest Only Period Extension Event has occurred on or prior
to June 30, 2016, the principal payment otherwise due and payable on July 1, 2016 shall be suspended but due and payable in full
no later than May 1, 2017, and (d) only if the Interest Only Period Extension Event has occurred on or prior to June 30, 2016,
the principal payment otherwise due and payable on August 1, 2016 shall be suspended but due and payable in full no later than
June 1, 2017. The entire principal balance of the Term Loan Advance and all accrued but unpaid interest hereunder, and all other
Secured Obligations with respect to the Term Loan Advance, shall be due and payable on the Term Loan Maturity Date.  Borrower
shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense.
Lender will initiate debit entries to Borrower’s account as authorized on the ACH Authorization (i) on each payment date
of all periodic obligations payable to Lender under the Term Advance and (ii) out-of-pocket legal fees and costs incurred by Agent
or Lender in connection with Section 11.11 of this Agreement.  Once repaid, the Term Loan Advance or any portion thereof may
not be reborrowed.”

 

		D.	Section 2.5 (End of Term Charge). The Loan Agreement is amended by deleting the first
sentence of Section 2.5 thereof in its entirety and inserting in lieu thereof the following:

 

“On
the earliest to occur of (i) February 1, 2017, (ii) the date that Borrower prepays the outstanding Secured Obligations, or (iii)
the date that the Secured Obligations otherwise become due and payable in accordance with the terms of this Agreement, Borrower
shall pay Lender a charge equal to Five Hundred Twenty Thousand Dollars ($520,000) (the “End of Term Charge”).”

 

		E.	Section 3 (Security Interest). The Loan Agreement is amended by deleting Section
3.1 thereof and its entirety and inserting in lieu thereof the following:

 

“3.1          As
security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the Secured Obligations,
Borrower grants to Agent and to Lender a security interest in all of Borrower’s right, title, and interest in and to the
following personal property whether now owned or hereafter acquired (collectively, the “Collateral”): (a) Receivables;
(b) Equipment; (c) Fixtures; (d) General Intangibles; (e) Inventory; (f) Investment Property (but excluding thirty-five percent
(35%) of the capital stock of any foreign Subsidiary that constitutes a Permitted Investment, but including all of the capital
stock in ISR Borrower); (g) Deposit Accounts; (h) Cash (including, without limitation, all cash and liquid funds); (i) Goods; and
all other tangible and intangible personal property of Borrower whether now or hereafter owned or existing, leased, consigned by
or to, or acquired by, Borrower and wherever located, and any of Borrower’s property in the possession or under the control
of Agent; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions
and replacements for, and rents, profits and products of each of the foregoing.”

 

    	2

     

    

 

		F.	Section 12 (Agency). The Loan Agreement is amended by inserting therein the following new
Section 12, immediately following Section 11 thereof:

 

“12.        AGENCY

 

12.1          Lender
hereby irrevocably appoints Hercules Capital, Inc. to act on its behalf as the administrative agent for itself and the Lender (in
such capacity, the “Agent”) hereunder and under the other Loan Documents and authorizes the Agent to take such
actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof or thereof, together with such
actions and powers as are reasonably incidental thereto.”

 

3.            Conditions
to Effectiveness. Lender and Borrower agree that this Amendment shall become effective upon the satisfaction of
the following conditions precedent, each in form and substance satisfactory to Lender:

 

(a)          Lender
shall have received a fully-executed counterpart of this Amendment signed by Borrower;

 

(b)          As
of the 2016 Amendment Date, no fact or condition exists that would (or would, with the passage of time, the giving of notice, or
both) constitute an Event of Default; and

 

(c)          Lender
shall have received payment for all fees and expenses incurred by Lender in connection with this Amendment, including, but not
limited to, all legal fees and expenses.

 

4.            Representations
and Warranties. The Borrower hereby represents and warrants to Lender as follows:

 

(a)          Representations
and Warranties in the Agreement. The representations and warranties of Borrower set forth in Section 5 of the Loan Agreement
are true and correct in all material respects on and as of the Effective Date with the same effect as though made on and as of
such date, except to the extent such representations and warranties expressly relate to an earlier date.

 

(b)          Authority,
Etc. The execution and delivery by Borrower of this Amendment and the performance by Borrower of all of its agreements and
obligations under the Loan Agreement and the other Loan Documents, as amended hereby, are within the corporate authority of Borrower
and have been duly authorized by all necessary corporate action on the part of Borrower. With respect to Borrower, the execution
and delivery by Borrower of this Amendment does not and will not require any registration with, consent or approval of, or notice
to any Person (including any governmental authority).

 

(c)          Enforceability
of Obligations. This Amendment, the Loan Agreement and the other Loan Documents, as amended hereby, constitute the legal, valid
and binding obligations of Borrower enforceable against Borrower in accordance with their terms, except as enforceability is limited
by bankruptcy, insolvency, reorganization, moratorium, general equitable principles or other laws relating to or affecting generally
the enforcement of, creditors’ rights and except to the extent that availability of the remedy of specific performance or
injunctive relief is subject to the discretion of the court before which any proceeding therefor may be brought.

 

    	3

     

    

 

(d)          No
Default. Before and after giving effect to this Amendment (i) no fact or condition exists that would (or would, with the passage
of time, the giving of notice, or both) constitute an Event of Default, and (ii) no event that has had or could reasonably be expected
to have a Material Adverse Effect has occurred and is continuing.

 

5.            Reaffirmations.
Except as expressly provided in this Amendment, all of the terms and conditions of the Loan Agreement and the other Loan Documents
remain in full force and effect. Nothing contained in this Amendment shall in any way prejudice, impair or effect any rights or
remedies of Lender under the Loan Agreement and the other Loan Documents. Except as specifically amended hereby, Borrower hereby
ratifies, confirms, and reaffirms all covenants contained in the Loan Agreement and the other Loan Documents. The Loan Agreement,
together with this Amendment, shall be read and construed as a single agreement. All references in the Loan Documents to the Loan
Agreement or any other Loan Document shall hereafter refer to the Loan Agreement or any other Loan Document as amended hereby.

 

6.            Execution
in Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original,
but which together shall constitute one instrument.

 

7.             Miscellaneous.

 

(a)          THIS
AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF CALIFORNIA, EXCLUDING
CONFLICT OF LAWS PRINCIPLES THAT WOULD CAUSE THE APPLICATION OF LAWS OF ANY OTHER JURISDICTION.

 

(b)          The
captions in this Amendment are for convenience of reference only and shall not define or limit the provisions hereof.

 

(c)          This
Amendment expresses the entire understanding of the parties with respect to the transactions contemplated hereby. No prior negotiations
or discussions shall limit, modify, or otherwise affect the provisions hereof.

 

(d)          Any
determination that any provision of this Amendment or any application hereof is invalid, illegal or unenforceable in any respect
and in any instance shall not affect the validity, legality, or enforceability of such provision in any other instance, or the
validity, legality or enforceability of any other provisions of this Amendment.

 

[Remainder of this
page intentionally left blank]

 

    	4

     

    

 

IN WITNESS WHEREOF,
Agent, Borrower and Lender have duly executed and delivered this Amendment as of the day and year first above written.

 

	 	BORROWER:
	 	 
	 	INSPIREMD, INC.
	 	 
	 	By:	/s/ Craig Shore
	 	Name:	Craig Shore
	 	Its:	CFO
	 	 
	 	INSPIRE M.D LTD
	 	 
	 	By:	/s/ Craig Shore
	 	Name:	Craig Shore
	 	Its:	CFO

 

Accepted in Palo Alto, California:

 

	 	AGENT:
	 	 	 
	 	HERCULES CAPITAL, INC.
	 	 	 
	 	By:	/s/ Ben Bang
	 	 	 
	 	Name:	Ben Bang
	 	 	 
	 	Its:	Associate General Counsel

 

	 	LENDER:
	 	 
	 	HERCULES CAPITAL, INC.
	 	 	 
	 	By:	/s/ Ben Bang
	 	Name:	Ben Bang
	 	Its:	Associate General Counsel

 

    	5Exhibit 10.4

 

AMENDMENT
TO DEBENTURE OF FIXED CHARGE 

 

This
amendment (the “Amendment”) to the Debenture of Fixed Charge dated October 23, 2013, as amended, modified, restated,
replaced or supplemented and as may be further amended, modified, restated, replaced or supplemented from time to time in accordance
with its terms (the “Debenture”) is made as
of June 13, 2016 by and among Inspire M.D Ltd., a limited liability company organised and existing under the laws of the
State of Israel with its registered office at 4 Menorat Hamaor St., Tel Aviv, 6744831, Israel, company number 51-367943-1 (the
“Pledgor”), and Hercules Capital, Inc., a Maryland corporation with its registered office at 400 Hamilton
Avenue, Suite 310, Palo Alto, California 94301 (the “Lender”) and Hercules Capital, Inc., a Maryland corporation
with its registered office at 400 Hamilton Avenue, Suite 310, Palo Alto, California 94301 in its capacity as administrative agent
for itself and the Lenders under the Loan Agreement (in such capacity, the “Agent”). All terms capitalized and
not otherwise defined hereunder shall have the meanings assigned to such terms under the Debenture.

 

WHEREAS, the
Lender, the Pledgor and the its parent company InspireMD, Inc. have entered into that certain loan arrangement dated as
of October 23, 2013, evidenced by, among other documents, a certain Loan and Security Agreement dated as of October 23, 2013 (hereinafter,
as may be amended, restated, replaced or supplemented from time to time in accordance with its terms, and together with the Loan
Documents (as defined thereunder), collectively, the “Loan Agreement”) and in connection with that Loan Agreement,
the Pledgor and the Lender wish to amend the provisions of the Debenture as set forth herein.

 

NOW THEREFORE, the Parties agree
as follows:

 

		1.	Description of Change in Terms:

 

		A.	The first paragraph of the preamble shall be replaced
in its entirety with the following:

 

“WHEREAS,
the undersigned, Inspire M.D Ltd, a limited liability company organised and existing under the laws of the State of
Israel with its registered office at 4 Menorat Hamaor St., Tel Aviv, 6744831, Israel (hereinafter: the
“Pledgor”), intends to receive, jointly and severally with its parent company, InspireMD, Inc.
(hereinafter: the “Parent”) from several banks and other financial institutions or entities from time to
time parties to the Loan Agreement (as defined below) (collectively, the “Lender”), including Hercules
Capital, Inc., a Maryland corporation with its registered office at 400 Hamilton Avenue, Suite 310, Palo Alto, California
94301 in its capacity as administrative agent for itself and the Lenders (in such capacity, the “Agent”),
a loan or loans, for such purpose and on such conditions as specified in the provisions of that certain Loan and Security
Agreement entered into between and among the Lenders, the Pledgor and the Parent on October 23rd, 2013, as amended
from time to time (hereinafter, as may be amended, restated, replaced or supplemented from time to time in accordance with
its terms, and together with the Loan Documents (as defined thereunder), collectively, the “Loan
Agreement”);”

 

     

     

    

 

		B.	Section 2 of the Debenture shall be replaced in its
entirety with the following:

 

"     2.        As
collateral security for the full and punctual payment of all of the Secured Sums (whether at stated maturity, acceleration or otherwise),
and without derogating from any other security, the Pledgor hereby absolutely and unconditionally charges and pledges to the Lender
and its successors by way of a first ranking fixed charge and pledge, and by an assignment by way of pledge, as applicable, (A)
(i) all Pledgor's rights to receive funds from its customers listed under Appendix A attached hereto (the “Customers
List”), and (ii) each outstanding account as specified in Appendix B attached hereto (the “Pledged
Accounts”), and (B) all Pledgor's rights, whether now existing or thereafter created (i) in and to all copyright rights,
copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether
published or unpublished, and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired
or held (“Copyrights”), including without limitation as specified in Appendix C attached hereto;
(ii) in and to all patents, patent applications and like protections, including without limitation improvements, divisions, continuations,
renewals, reissues, extensions, and continuations-in-part of the same (“Patents”), including without limitation
as specified in Appendix D attached hereto; (iii) in and to all trademark and service mark rights, whether registered
or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of
Pledgor connected with and symbolized by such trademarks (“Trademarks”), including without limitation as specified
in Appendix E attached hereto; (iv) in and to all mask works or similar rights available for the protection of semiconductor
chips, now owned or hereafter acquired (“Mask Works”), including, without limitation as specified in Appendix
F; (v) in and to all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions,
know-how, operating manuals; (vi) in and to all source code; (vii) in and to all design rights; (viii) in and to all claims for
damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligation, to sue
for and collect such damages for said use or infringement of the intellectual property rights identified above; and (ix) in and
to all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter
existing, created, acquired or held; (x) in and to all amendments, renewals and extensions of any of the Copyrights, Trademarks,
Patents and Mask Works; in all cases whether now owned or hereafter acquired by Pledgor; (xi) in and to all licenses or other rights
to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the
extent permitted by such license or rights; (xii) to all proceeds and products of the foregoing, including, without limitation,
all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing; and (C) all the fixed assets
listed under Appendix G (the “Equipment List”) (hereinafter (A), (B) and (C), jointly and severally,
the "Charged Property”).

 

It is hereby
agreed and acknowledged that the description of the Charged Property, including without limitations, the Customers List, Pledged
Accounts, Copyrights, Patents, Trademarks, Mask Works and Equipment List, shall be amended and updated from time to time by the
Pledgor, in accordance with the provisions hereof and the provisions of the Loan Agreement."

 

		C.	The following shall be added as Section 33 of the
Debenture:

 

"            AGENCY

 

33.          Lenders
hereby irrevocably appoints Hercules Capital, Inc. to act on their behalf as the administrative agent for itself and the Lenders
(in such capacity, the “Agent”) hereunder and authorizes the Agent to take such actions on its behalf and to exercise
such powers as are delegated to the Agent by the terms hereof or thereof, together with such actions and powers as are reasonably
incidental thereto. It is hereby noted that all rights granted herein to the Lender shall be deemed as granted to the Agent for
the ratable benefit of the Lenders.”

 

		2.	The above mentioned Appendixes shall be attached hereto as integral part hereof and as integral
part of the Debenture.

 

     

     

    

 

		3.	Except as specifically set forth herein, none of the terms of the Debenture shall be in any way
modified by this Amendment, and all such terms and conditions shall remain in full force and effect.

 

		4.	This Addendum is made in accordance with Section 29 of the Debenture, and constitutes (together
with any appendix attached hereof) an integral part thereof.

 

-signature
page follows-

 

     

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Amendment to be signed on the date first above written.

 

	/s/ Ben Bang	 
	HERCULES CAPITAL, INC. [also in its capacity as Agent]	 
	By:	Ben Bang	 
	Title:	Associate General Counsel	 
	 	 	 
	/s/ Craig Shore	 
	INSPIRE M.D LTD	 
	By:	Craig Shore	 
	Title:	CFO	 

 

     

     

    

 

Appendix A

Customers List

 

	Company	 	Country
	CMS Produtos Medicos Ltda (OLD)	 	Brazil
	Dispomed Promet	 	Croatia
	Medreto OU	 	Estonia
	Dr. Osypka GmbH	 	Germany
	Tzamal Jakobsohn Ltd	 	Israel
	KIRLOSKAR TECHNOLOGIES (P) LTD	 	India
	Euromed GmbH	 	Austria
	Sigma Medical B.V.	 	Netherlands
	Bosti Trading Ltd.	 	Cyprus
	Dream Technology L.P.	 	United Kingdom
	Charles de Giorgio Ltd.	 	Malta
	Premier G. Med Cardio Ltd	 	Hungary
	Torque Medical	 	South Africa
	Stimcare	 	Czech Republic
	Fortimed	 	Spain
	Grex Medical Oy	 	Finland
	Tecmed SRL	 	Romania
	Vascular Perspectives Ltd	 	United Kingdom
	Meliora Medtech AB	 	Sweden
	lnselspital Bern	 	Switzerland
	Hospital Fribourgeols	 	Switzerland
	Chi Le Raincy Montfermeil	 	France
	Groupe Hospitalier Mutualiste	 	France
	CHUV	 	Switzerland
	Bay Medical Pty Ltd	 	Australia
	CENTRE HOSPITALIER D AVIGNON	 	France
	GlobalMed a.s.	 	Slovakia
	Universitatsmedizin Rostock	 	Germany
	CMS Chile	 	Chile
	CHU Besancon (not active)	 	France
	CH Haguenau	 	France
	PLN Szpital Uniwersytecki w Krakowie	 	Poland
	Katedra i Klinika Kardiologii Uniwersytetu Medyc	 	Poland
	University Hospitals Southampton NHS Foundation	 	United Kingdom
	Vingmed AS. Norway	 	Norway
	KAUF Klinikum Fulda gAG	 	Germany
	Clinique Pasteur	 	France
	SLK Kliniken Heilbronn GmbH	 	Germany
	Centre Hospitalier de la region Anneciennc	 	France
	Charite - Universitatsmedizin Berlin - CVK	 	Germany
	Kardiologische Praxis Prof. Dr. Silber	 	Germany

 

    1 

     

    

 

	lnstitut Jacques Cartier	 	France
	HJK Erkelenz/Am Schneller	 	Germany
	Centre Hospitalier de LA CAVALE BLANCHE	 	France
	CHU Jean Minjoz Besancon	 	France
	SPZOZ, Pracownia Hemodynamiki	 	Poland
	Waldkrankenhaus	 	Germany
	SAS CLINIQUE GENERALE DE MARIGNANE	 	France
	Antwerp Cardiovascular Institute, AZ Middelheim	 	Belgium
	G.C.S. Cardio CHRA	 	France
	Krakowskie Centrum Kardiologii	 	Poland
	CHU Gabriel Montpied	 	France
	Clinique Saint-Vincent	 	France
	Sana-Herzzentrum Cottbus GmbH	 	Germany
	Herzzentrum Dresden GmbH	 	Germany
	Cardiology Associates of North MS/Research, LLC	 	United States
	SIA Scanmed	 	Latvia
	CARDIO MEDICAL D.O.O.	 	Slovenia
	Unfallkrankenhaus Berlin	 	Germany
	Vingmcd Sweden	 	Sweden
	polyclinique des fleurs	 	France
	Medilex Limited	 	Ireland
	Hopital Claude Galien ICPS	 	France
	Sz.P. Wieslaw Mazurek	 	Poland
	Hopital haut leveque-CHU de Bordeaux	 	France
	CHU de Toulouse hopital de Rangueil	 	France
	Kardia	 	Italy
	Uniwersytecki Szpital Kliniczny	 	Poland
	Avidal Group GMBH	 	Germany
	JSC Medikamcntu tinklas Co.	 	Lithuania
	HELIOS Klinikum Aue	 	Germany
	Uniwersyteckie Centrum Kliniczne	 	Poland
	Wojskowym Instytutem Medycznym	 	Poland
	Izasa Hospital SLU	 	Spain
	Uniwersytetu Medycznego w Lodzi	 	Poland
	Klinika Kardiologii i Angiologii Interwencyjnej	 	Poland
	Charite Universitatsklinikum Berlin Campus Virch	 	Germany
	Charite Universitatsklinikum Berlin Campus Benja	 	Germany
	Cardiff University Hospitals	 	United Kingdom
	Sheffield Teaching Hospitals	 	United Kingdom
	Universitatsklinikum Magdeburg A.o.R.	 	Germany
	Petr Jerabek	 	Czech Republic
	Jan Winten	 	Belgium
	Christopher MacLeod	 	United Kingdom
	Miki Olsher	 	Israel
	Stephane Viney	 	France
	Vivianc Barbieri	 	Brazil

 

    2 

     

    

 

	Dominika Chudzik	 	Poland
	Eduard Kasper	 	Germany
	Paul Jeffers	 	United Kingdom
	Jane Bettoni	 	Italy
	Sieglinde Reik-Lingen	 	Germany
	Piet van den Bosch	 	Netherlands
	Juan Rigla	 	Spain
	Kim Vandeweyer	 	Belgium
	Rick Olson	 	United Kingdom
	Pavel Minkov	 	Israel
	Ralph Essers	 	Netherlands
	Jens Ten Doornkaat	 	Germany
	Giancarlo Fasulo	 	Italy
	TIP Profiles Karolina Mendocha	 	Poland
	Augusta-Krankcnhaus VKKD	 	Germany
	Logis-Med Sp. Zo.o.	 	Poland
	VASMO Medical Group	 	Poland
	Centre Hospitalier St. Joseph et st Luc 2	 	France
	Avidal Group GMBH as Agent	 	Germany
	Klinikum Stadt Soest	 	Germany
	Herz- und Diabeteszentrum NRW	 	Germany
	Manchester Royal Infirmary	 	United Kingdom
	Austro Line d.o.o.	 	Monaco
	I.R.C.C.S. Policlinico San Donato	 	Italy
	Azienda ULSS 13 MIRANO Regione Veneta	 	Italy
	Hairmyres NHS Trust OCT	 	United Kingdom
	Sheba Medical Center	 	Israel
	Stefano Cova	 	Italy
	Herzklinik Dres Harer	 	Germany
	Sunderland Hospital	 	United Kingdom
	CARDIO MEDICAL SALES L.P.	 	Lithuania
	Nathalie Barthelemy	 	France
	MCZ-Hemodynamika	 	Poland
	Kaster Srl	 	Italy
	Norfolk and Norwich University Hospital- OCT	 	United Kingdom
	Morriston Hospital- OCT	 	United Kingdom
	Papworth Hospital NHS Foundation Trust- OCT	 	United Kingdom
	University Hospitals of South Manchester- OCT	 	United Kingdom
	Hairmyres NHS Trust	 	United Kingdom
	Freeman Hospital	 	United Kingdom
	SAMODZIELNY PUBLICZNY ZOZ WOJE	 	Poland
	Shaare Zedek Medical Center	 	Israel
	מ”עבעשירא	 	Israel
	CROSSMED S.r.1.	 	Italy
	Carlos Haya Hospital	 	Spain
	LMR A.O.U. Citta delta Salute e della	 	Italy

 

    3 

     

    

 

	LMR Ospedale Policlinico Santa Maria	 	Italy
	Cyvital Enterprises Limited	 	Cyprus
	Piotr Musialek	 	Poland
	ULSS 13 Mirano - Presidio de Mirano - LMR	 	Italy
	Pauls Stradins Clinical University Hospital -LMR	 	Latvia
	VIDE BULA	 	Brazil
	E-Symbion SRL	 	Romania
	ProCardia Medical Sp. z o.o.	 	Poland
	Carmel Medical Center	 	Israel
	Prof. Schofer	 	Poland
	Rothschild Hospital	 	France
	CHU Grenoble	 	France
	INMED Com. de Mat. Hosp. Ltda	 	Brazil
	INTUIT	 	Brazil
	TECNOMEDICAL	 	Brazil
	Somma Produtos Hospitalares LTDA	 	Brazil
	Penumbra Europe GmbH	 	Germany
	Endovix	 	Brazil
	The Queen Elizabeth University Hospital	 	United Kingdom
	SUPRI Medical and Hospital Devices Ltda	 	Brazil
	WORLD MEDICAL S.A.S.	 	Colombia
	lmportadora y Exportadora CAMIR LTDA	 	Chile
	Pro Gem	 	Slovenia
	Osypka AG	 	Germany
	Barts and The London NHS Trust	 	United Kingdom
	Med-All International	 	Germany
	Mediscape	 	Malaysia
	Angiocor S.A.	 	Argentina
	Svelte Medical Systems, Inc.	 	United States
	EURO MEKO	 	Germany
	QUALIMED	 	Germany
	BCH	 	Canada
	Natec Medical Ltd.	 	Mauritius
	Cardiovascular Interventional Concepts (CIC)	 	Brazil
	LEVBETH MEDICAL SA DE CV	 	Mexico
	MedlineS Kft.	 	Hungary
	KEBOMED AS	 	Denmark
	Endo Tech s.r.o	 	Czech Republic

 

[END OF EXHIBIT A]

 

    4 

     

    

 

Appendix B

Pledged Accounts

 

Det Trial Bal: Acct Curr & USD

6/8/2016

 

	Curr	 	Account No.	 	 	Account Description	 	Balance (ILS)	 	 	Bal (USD)	 	 	Bal (Acct Curr)	 	 	Curr
	1**.ASSETS	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	10*.CURRENT ASSETS	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	104.Accounts Receivable- Clients	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	100021	 	 	Tzamal Jakobsohn Ltd	 	 	243,941.71	 	 	 	64,338.97	 	 	 	 	 	 	 
	Total	 	 	 	 	 	 	 	 	243,941.71	 	 	 	64,338.97	 	 	 	0	 	 	 
	CHF	 	 	100068	 	 	CHUV	 	 	3,746.60	 	 	 	996.17	 	 	 	963.36	 	 	CHF
	Total	 	 	 	 	 	 	 	 	3,746.60	 	 	 	996.17	 	 	 	963.36	 	 	CHF
	EUR	 	 	100015	 	 	Medreto OU	 	 	1,711.52	 	 	 	453.98	 	 	 	400	 	 	EUR
	 	 	 	100036	 	 	Bosti Trading Ltd.	 	 	-31,014.72	 	 	 	-8,246.40	 	 	 	-7,260.51	 	 	EUR
	 	 	 	100054	 	 	Torque Medical	 	 	-137.76	 	 	 	-17.98	 	 	 	 	 	 	EUR
	 	 	 	100057	 	 	Grex Medical Oy	 	 	-427.17	 	 	 	-113.58	 	 	 	-100	 	 	EUR
	 	 	 	100058	 	 	Tecmed SRL	 	 	22,499.75	 	 	 	5,929.17	 	 	 	5,250.00	 	 	EUR
	 	 	 	100071	 	 	GlobalMed a.s.	 	 	30,772.13	 	 	 	8,093.11	 	 	 	7,145.00	 	 	EUR
	 	 	 	100097	 	 	Institut Jacques Cartier	 	 	5,094.19	 	 	 	1,347.06	 	 	 	1,185.78	 	 	EUR
	 	 	 	100121	 	 	G.C.S. Cardio CHRA	 	 	9,256.31	 	 	 	2,467.07	 	 	 	2,171.56	 	 	EUR
	 	 	 	100137	 	 	polyclinique des fleurs	 	 	-115.81	 	 	 	-30.79	 	 	 	-27.11	 	 	EUR
	 	 	 	100139	 	 	Hopital Claude Galien ICPS	 	 	4,210.96	 	 	 	1,119.64	 	 	 	985.78	 	 	EUR
	 	 	 	100142	 	 	Hopital haut leveque-CHU de Bordeaux	 	 	4,168.82	 	 	 	1,119.50	 	 	 	985.78	 	 	EUR
	 	 	 	100144	 	 	Kardia	 	 	67,940.45	 	 	 	18,064.46	 	 	 	15,904.78	 	 	EUR
	 	 	 	100146	 	 	Avidal Group GMBH	 	 	80,372.52	 	 	 	20,931.35	 	 	 	18,700.00	 	 	EUR
	 	 	 	100159	 	 	Izasa Hospital SLU	 	 	108,984.02	 	 	 	28,689.59	 	 	 	25,320.00	 	 	EUR
	 	 	 	100229	 	 	Centre Hospitalier St. Joseph et st Luc 2	 	 	2,121.10	 	 	 	560.55	 	 	 	492.89	 	 	EUR
	 	 	 	100230	 	 	Avidal Group GMBH as Agent	 	 	2,801.51	 	 	 	716.5	 	 	 	658.45	 	 	EUR
	 	 	 	100249	 	 	Kaster Srl	 	 	124,500.75	 	 	 	33,366.48	 	 	 	29,150.00	 	 	EUR
	 	 	 	100262	 	 	CROSSMED S.r.l.	 	 	118,126.56	 	 	 	30,948.36	 	 	 	27,360.00	 	 	EUR
	 	 	 	100266	 	 	Cyvital Enterprises Limited	 	 	6,806.32	 	 	 	1,820.58	 	 	 	1,600.00	 	 	EUR
	 	 	 	100293	 	 	MedlineS Kft.	 	 	-3,359.23	 	 	 	-736.02	 	 	 	-786.53	 	 	EUR
	 	 	 	100295	 	 	Endo Tech s.r.o	 	 	-59.9	 	 	 	-14.42	 	 	 	 	 	 	EUR
	Total	 	 	 	 	 	 	 	 	554,252.32	 	 	 	146,468.21	 	 	 	129,135.87	 	 	EUR
	GBP	 	 	100254	 	 	Hairmyres NHS Trust	 	 	118.43	 	 	 	31.49	 	 	 	21.59	 	 	GBP
	 	 	 	100255	 	 	Freeman Hospital	 	 	-3,250.20	 	 	 	-831.25	 	 	 	-600	 	 	GBP
	 	 	 	100297	 	 	Asteral Services Ltd	 	 	428.05	 	 	 	114.24	 	 	 	78	 	 	GBP
	Total	 	 	 	 	 	 	 	 	-2,703.72	 	 	 	-685.52	 	 	 	-500.41	 	 	GBP
	PLN	 	 	100227	 	 	Logis-Med Sp. Z o.o.	 	 	-7,209.62	 	 	 	-1,843.89	 	 	 	-7,250.00	 	 	PLN
	Total	 	 	 	 	 	 	 	 	-7,209.62	 	 	 	-1,843.89	 	 	 	-7,250.00	 	 	PLN
	USD	 	 	100050	 	 	Temp USD	 	 	-165.48	 	 	 	-44	 	 	 	-44	 	 	USD
	 	 	 	100129	 	 	SIA Scanmed	 	 	31,451.49	 	 	 	8,237.50	 	 	 	8,237.50	 	 	USD
	 	 	 	100243	 	 	CARDIO MEDICAL SALES L.P	 	 	525,895.00	 	 	 	134,500.00	 	 	 	134,500.00	 	 	USD
	 	 	 	100285	 	 	Penumbra Europe GmbH	 	 	132,652.31	 	 	 	30,615.00	 	 	 	30,615.00	 	 	USD
	 	 	 	100288	 	 	SUPRI Medical and Hospital Devices Ltda	 	 	-166.95	 	 	 	0	 	 	 	 	 	 	USD
	 	 	 	100291	 	 	Cardiovascular Interventional Concepts (CIC)	 	 	133	 	 	 	0	 	 	 	 	 	 	USD
	 	 	 	100292	 	 	LEVBETH MEDICAL SA DE CV	 	 	4,270.20	 	 	 	0	 	 	 	 	 	 	USD
	 	 	 	100294	 	 	KEBOMED AS	 	 	43,968.65	 	 	 	11,000.00	 	 	 	11,000.00	 	 	USD
	 	 	 	207136	 	 	provision for returns	 	 	75.22	 	 	 	20	 	 	 	20	 	 	USD
	 	 	 	300023	 	 	Angiocor S.A	 	 	102,527.00	 	 	 	27,000.00	 	 	 	27,000.00	 	 	USD
	Total	 	 	 	 	 	 	 	 	840,640.44	 	 	 	211,328.50	 	 	 	211,328.50	 	 	USD
	105.Accounts Receivable- Doubtful	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	EUR	 	 	100027	 	 	Novalab France	 	 	266,498.55	 	 	 	70,858.43	 	 	 	62,387.00	 	 	EUR
	 	 	 	100028	 	 	Euromed Deutschland GmbH	 	 	748,246.48	 	 	 	198,948.81	 	 	 	175,163.63	 	 	EUR
	 	 	 	100029	 	 	Euromed GmbH	 	 	23,921.52	 	 	 	6,360.41	 	 	 	5,600.00	 	 	EUR
	 	 	 	100034	 	 	Slainte Solutions Ltd	 	 	62,443.71	 	 	 	16,602.95	 	 	 	14,618.00	 	 	EUR
	 	 	 	101111	 	 	Provision for bad debts Euro	 	 	-1,101,239.86	 	 	 	-292,805.07	 	 	 	-257,798.97	 	 	EUR
	Total	 	 	 	 	 	 	 	 	-129.6	 	 	 	-34.47	 	 	 	-30.34	 	 	EUR
	GBP	 	 	100190	 	 	Cardiff University Hospitals	 	 	3,016.86	 	 	 	802.14	 	 	 	550	 	 	GBP
	 	 	 	101112	 	 	Provision for bad debts GBP	 	 	-3,016.86	 	 	 	-802.14	 	 	 	-550	 	 	GBP
	Total	 	 	 	 	 	 	 	 	0	 	 	 	0	 	 	 	0	 	 	GBP
	USD	 	 	100273	 	 	E-Symbion SRL	 	 	18,924.14	 	 	 	5,021.00	 	 	 	5,021.00	 	 	USD
	 	 	 	101113	 	 	Provision for bad debts $	 	 	-18,883.98	 	 	 	-5,021.00	 	 	 	-5,021.00	 	 	USD
	Total	 	 	 	 	 	 	 	 	40.16	 	 	 	0	 	 	 	0	 	 	USD
	TOTAL	 	 	 	 	 	 	 	 	1,632,578.29	 	 	 	420,567.97	 	 	 	 	 	 	USD

 

     

     

    

 

Appendix C

Copyrights

 

None.

 

     

     

    

 

Appendix D

Patents

 

	Description	 	Registration/

    Application

    Number (Country)	 	Registration/

    Application

    Date
	 	 	 	 	 
	Optimized Stent Jacket	 	198,665 (IL)	 	Nov. 21, 2007; issued May 28, 2014
	 	 	 	 	 
	Optimized Stent Jacket	 	ZL200780043259.2 (CN)	 	Nov. 21, 2007; issued Jan. 2, 2013
	 	 	 	 	 
	Optimized Drug-Eluting Stent Assembly	 	9,132,003 (US); 14/314,777	 	June 24, 2014; issued Jan. 2, 2013
	 	 	 	 	 
	Optimized Stent Jacket	 	ZL201210454357.8 (CN)	 	Nov. 13, 2013; issued Dec. 9, 2015
	 	 	 	 	 
	Bifurcated Stent Assemblies	 	198,188 (IL)	 	Oct. 18, 2007; issued May 1, 2014
	 	 	 	 	 
	In Vivo Filter Assembly	 	8,043,323 (US); 11/582,354	 	Oct. 18, 2006; issued Oct. 25, 2011
	 	 	 	 	 
	Bifurcated Stent Assemblies	 	8,961,586 (US); 11/797,168	 	May 1, 2007; issued Feb. 24, 2015
	 	 	 	 	 
	In Vivo Filter Assembly	 	9,132,261 (US); 13/237,977	 	Sept. 21, 2011; issued Sept. 15, 2015
	 	 	 	 	 
	Bifurcated Stent Assemblies	 	ZL200780046676.2 (CN)	 	Issued Sept. 26, 2012
	 	 	 	 	 
	Stent Apparatuses For Treatment Via Body Lumens And Methods Of Use	 	2,609,687 (CA)	 	May 24, 2006; issued April 22, 2014
	 	 	 	 	 
	Stent Apparatuses For Treatment Via Body Lumens And Methods Of Use	 	2,843,097 (CA)	 	Feb. 20, 2014; issued Oct. 27, 2015
	 	 	 	 	 
	Stent Apparatuses For Treatment Via Body Lumens And Methods Of Use	 	2007/10751 (ZA)	 	Issued Oct. 27, 2010
	 	 	 	 	 
	Filter Assemblies	 	198189 (IL)	 	Oct. 18, 2007; issued Mar. 27, 2014

 

     

     

    

 

	Filter Assemblies	 	2,666,712 (CA)	 	Oct. 18, 2007; issued Mar. 31, 2015
	 	 	 	 	 
	Filter Assemblies	 	ZL200780046659.9 (CN)	 	Oct. 18, 2007; issued Mar. 31, 2015
	 	 	 	 	 
	Filter Assemblies	 	201210119132.7 (CN)	 	Oct. 18, 2007
	 	 	 	 	 
	Knitted Stent Jackets	 	198190 (IL)	 	Oct. 18, 2007; issued Feb. 1, 2014
	 	 	 	 	 
	Knitted Stent Jackets	 	ZL200780046697.4 (CN)	 	Issued Oct. 10, 2012; expires Oct. 17, 2027
	 	 	 	 	 
	Knitted Stent Jackets	 	2,666,728 (CA)	 	Oct. 18, 2007; issued June 23, 2015
	 	 	 	 	 
	Knitted Stent Jackets	 	ZL201210320950.3 (CN)	 	Oct. 18, 2007; issued Dec. 2, 2015
	 	 	 	 	 
	Stent with Sheath and Metal Wire	 	14/315,001 (US); 2014/0309723	 	June 25, 2014
	 	 	 	 	 
	Stent with Sheath and Metal Wire and Methods	 	14/705,871 (US); 2015/0230953	 	May 6, 2015
	 	 	 	 	 
	Optimized Stent Jacket	 	12/791,008 (US); 2010/0241214	 	June 1, 2010
	 	 	 	 	 
	Intravascular Aneurysm Treatment Device And Methods 	 	14/935,339 (US); 2016/0058589	 	Nov. 6, 2015
	 	 	 	 	 
	Optimized Stent Jacket	 	07827415.6 (EP); EP2088962 A4	 	Nov. 21, 2007
	 	 	 	 	 
	Optimized Stent Jacket	 	230922 (IL)	 	Feb. 11, 2014
	 	 	 	 	 
	Optimized Stent Jacket	 	2,670,724 (CA)	 	Nov. 21, 2007
	 	 	 	 	 
	Optimized Stent Jacket	 	4008/DELNP/2009 (IN)	 	Nov. 21, 2007
	 	 	 	 	 
	Optimized Drug-Eluting Stent Assembly 	 	14/851,882 (US); 2015/0374519	 	Sept. 11, 2015
	 	 	 	 	 
	Bifurcated Stent Assemblies	 	3113/DELNP/2009 (IN)	 	Oct. 18, 2007
	 	 	 	 	 
	Stent Apparatuses For Treatment Via Body Lumens And Methods Of Use	 	EP 06745069.2 (EP); EP1885281 A2	 	May 24, 2006

 

     

     

    

 

	Stent Apparatuses For Treatment Via Body Lumens And Methods Of Use	 	11/920,972 (US); 2009/0138070	 	Nov. 23, 2007
	 	 	 	 	 
	Stent Apparatuses For Treatment Via Body Lumens And Methods Of Use	 	187516 (IL)	 	Nov. 20, 2007
	 	 	 	 	 
	Carotid Stent Assembly and Methods for Treatment Via Body Lumens 	 	14/500,759 (US); 2015/0032197	 	Sept. 29, 2014
	 	 	 	 	 
	Filter Assemblies	 	EP 2007 827228.3 (EP)	 	Oct. 18, 2007
	 	 	 	 	 
	Filter Assemblies	 	12/445,972 (US); 2010/0204772	 	Apr. 17, 2009
	 	 	 	 	 
	Filter Assemblies	 	2,881,557 (CA)	 	Feb. 6, 2015
	 	 	 	 	 
	Filter Assemblies	 	3114/DELNP/2009 (IN)	 	Oct. 18, 2007
	 	 	 	 	 
	Knitted Stent Jackets	 	EP 07827229.1 (EP); EP 2076212 A2	 	Oct. 18, 2005
	 	 	 	 	 
	Knitted Stent Jackets	 	12/445,980 (US); 2010/0324651	 	Apr. 17, 2009
	 	 	 	 	 
	Knitted Stent Jackets	 	3171/DELNP/2009 (IN)	 	Oct. 18, 2007
	 	 	 	 	 
	Knitted Stent Jackets	 	2,887,189 (CA)	 	Apr. 2, 2015
	 	 	 	 	 
	Stent Thermoforming Apparatus and Methods	 	14/505,310 (US); 2016/0096308	 	Oct. 2, 2014
	 	 	 	 	 
	Stent Thermoforming Apparatus and Methods	 	PCT/IB2015/057367	 	Sept. 24, 2015
	 	 	 	 	 
	Stent-Mesh Assembly And Methods	 	14/592,714 (US); 2015/0119971	 	Jan. 8, 2015
	 	 	 	 	 
	Stent with Sheath and Metal Wire Retainer	 	13/994,739 (US); 2013/0274858	 	Dec. 18, 2011
	 	 	 	 	 
	Deformable Tip For Stent Delivery And Methods Of Use	 	62/290,031 (US)	 	Feb. 2, 2016

 

[END OF EXHIBIT D]

 

     

     

    

 

Appendix E

Trademarks

 

	Description	 	Registration/

    Application

    Number (Country)	 	Registration/

    Application

    Date
	 	 	 	 	 
	CARENET	 	013399977 (EU)	 	Mar. 17, 2015
	 	 	 	 	 
	CGUARD	 	013370978 (EU)	 	Mar. 26, 2015
	 	 	 	 	 
	INSPIREMD	 	008642118 (EU)	 	Apr. 26, 2010
	 	 	 	 	 
	MGUARD	 	008642175 (EU)	 	Apr. 26, 2010
	 	 	 	 	 
	MGUARD PRIME	 	013366141 (EU)	 	Mar. 12, 2015
	 	 	 	 	 
	
        MICRONET (Class 10) (Supplemental
Registration)
	 	4,721,716 (US); 85/659,900	 	Apr. 14, 2015
	 	 	 	 	 
	MNP MicroNet Protection Logo	 	011737699 (EU)	 	Sept. 9, 2013
	 	 	 	 	 
	CARENET	 	86/261,697 (US)	 	Apr. 24, 2014
	 	 	 	 	 
	CGuard	 	86/364,984 (US)	 	Aug. 13, 2014
	 	 	 	 	 
	MGUARD PRIME	 	86/417,711 (US)	 	Oct. 8, 2014
	 	 	 	 	 
	InspireMD	 	86/702,932 (US)	 	July 23, 2015
	 	 	 	 	 
	SmartFit	 	86/702,941 (US)	 	July 23, 2015
	 	 	 	 	 
	PVGuard 	 	86/702,984 (US)	 	July 23, 2015
	 	 	 	 	 
	NGuard 	 	86/702,957 (US)	 	July 23, 2015
	 	 	 	 	 
	AGuard	 	86/702,971 (US)	 	July 23, 2015

 

     

     

    

 

Appendix F

Mask Works

 

None.

 

     

     

    

 

Appendix G

Equipment List

 

Distributed via e-mail.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]